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Letter to the Editor 
 
Individualized FSH dosing improves safety and reduces iatrogenic poor response while 
maintaining live-birth rates. 
 
Sir, 
We read with interest the trials published by the OPTIMIST trial group (Oudshoorn, et al., 2017, 
van Tilborg, et al., 2017, van Tilborg, et al., 2017). These three papers collectively suggest that the 
individualization of FSH dosing according to a baseline antral follicle count is not effective. We are 
concerned that this conclusion is driven by excessive reliance on live-birth rates, rather than 
outcomes which are directly modifiable by ovarian stimulation. Recognition of non-inferiority for 
live-birth rates, but the distinct advantages of fewer poor responses and improved patient safety 
with respect to a reduced risk of ovarian hyperstimulation syndrome (OHSS) have been reported in 
other trials examining individualization of ovarian stimulation (Allegra, et al., 2017, Nyboe 
Andersen, et al., 2017). We would suggest that the data from the OPTIMIST trials in fact confirms 
the benefits of individualized FSH dosing, and it is notable that these advantages were achieved 
despite the very limited stratification of doses (100, 150, 225 and 450IU) that were initially 
assessed.    
 
Specifically, the authors demonstrate that for the potential poor responder patient (van Tilborg, et 
al., 2017), individualization with increased doses of FSH reduces cycle cancellations (cancellation 
due to inadequate follicular response 30% in the 150IU arm as compared to 8% for 225IU or 4.4% 
for 450IU) and increases oocyte yield by one or two oocytes in the first treatment cycle (9.2 v 7.3 
and 6.4 v 5.3 oocytes). The authors are to be commended for retaining as many women in the trial, 
however, this experience is not universal and cycle cancellation is known to contribute to 
discontinuation of treatment, particularly if maximal stimulation has been used (Troude, et al., 
2014). To examine live-birth rates, a much larger sample size would have been required.  For 
example to show a relative 25% increase in live-birth rates from 20% to 25% for that first cycle in 
women with an AFC<10, over 2000 women would be required to be randomized. That there is a 
consistent linear association with live-birth rates in this range of oocytes (Steward, et al., 2014), 
particularly when fresh and frozen embryos are accounted for, would further support the need for a 
much larger trial, prior to definitively concluding that there is no benefit of increased doses on live-
birth rates from that first treatment cycle.  
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Likewise in (Oudshoorn, et al., 2017), cycle cancellation was increased with 100IU suggesting that 
at these low doses, additional factors like bodyweight that are inversely associated with FSH 
exposure need to be taken into account (Howles, et al., 2006, Ledger, et al., 2011) and confirms the 
need for robust modelling of dose selection prior to commencing an RCT examining individualised 
FSH doses. At the other extreme of ovarian response and the anticipated hyper-responder, the 
customization of therapy for the first treatment cycle results in a significant reduction in the rate of 
hyper-response (11.6% v 38.3%) as well as a reduced incidence of ovarian hyperstimulation 
syndrome (OHSS)(4.7% v 14.7%), while maintaining both fresh live birth rates (25.7% v 25.2%) 
and cumulative live birth rates (36.0% v 39.1%).  
 
We are somewhat surprised that, in light of these findings, the authors suggest that clinicians should 
use a standard dose of 150 units for all women entering an IVF programme regardless of their antral 
follicle count. We propose an alternative interpretation of the data, that individualization of ovarian 
stimulation reduces the variability of the number of oocytes recovered, increases the number of 
oocytes recovered in the poor responder and reduces the number of oocytes in the hyper responder. 
It reduces the proportion of women who have a poor or hyper-response, reduces the risk of 
cancellation of the cycle, increases the number of patients who reach embryo transfer and reduces 
the incidence of OHSS. Furthermore, it achieves all of this while maintaining live-birth rates. That 
some patients did not have an optimal outcome would suggest that alternative algorithms and 
biomarkers should be considered to individualize clinical dosing (Allegra, et al., 2017, Nyboe 
Andersen, et al., 2017). We would suggest that individualization of the dose of FSH is definitively 
superior to “a one-size fits all”, and when combined with data from other recent trials, 
individualization of gonadotropin dosing should now be the standard of care. 
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